866-997-4948(US-Canada Toll Free)

Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology

Published By :

GBI Research

Published Date : May 2011

Category :

Biotechnology

No. of Pages : 119 Pages


GBI Researchs report, Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology, provides in-depth analysis of innovations in protein kinase therapies in the current pharmaceutical market. 

The report analyzes the protein kinase pipelines of pharmaceutical companies by indication, and also according to the phase of clinical trial. This report includes protein kinase pipeline profiles of the top 10 pharmaceutical companies based on their pipeline. It gives you a robust idea on pipeline, innovations in various indications, new strategies employed for innovation, trends in combination drugs and protein kinase targets. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. 

The current R&D product pipeline targeting protein kinases consists of a majority of the molecules in Phase II. Phase II contains 57% of the total moleculse, followed by Phase I, Phase III, Pre-clinical, and Discovery phases, accounting to 29%, 8%, 5%, and 1% respectively. Oncology has the highest number of pipeline drugs, accounting for 92% of total indications. 

The pipeline seems to be outsized when compared with the last few years, and it is growing strategically with increased focus on protein kinases. In particular, the oncology indication gained a lot of attention, and protein kinases with their specificity took a major stake in oncology pipeline molecules.

Scope

The scope of this report includes - 

  • Detailed classification of protein kinase pipeline molecules.
  • Pipeline product analysis, category-wise and Phase-wise study.
  • Profiles of the top 10 companies with key pipeline products, indication-wise and Phase-wise analysis.
  • An overview of current innovative strategies in the protein kinase therapies development by pharmaceutical companies.

Reasons to buy

The report will aid business development and marketing executives in strategizing their product launches and help venture capitalists to identify promising small and medium sized enterprises. It will allow you to - 

  • Assess the strength of the protein kinase pipeline of current pharmaceutical companies.
  • Understand the potential areas of application for protein kinase therapies.
  • Identify key protein kinases in development based on the therapy.
  • Identify the key players investing in protein kinase therapies.
  • Optimize your R&D pipeline through identification and understanding of the key pipeline products of competitors.
  • Develop effective strategies related to innovations in protein kinase therapies by identifying the new targets in development.
Table of Contents

1 Table of Contents

1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 8

2 Protein Kinases Introduction 10
2.1 GBI Research Report Guidance 10

3 Protein Kinases Overview 11

3.1 Localization and Function in the Cell 11
3.2 The Human Kinome 11
3.3 Kinase Classification 12
3.3.1 AGC Family 13
3.3.2 CAMK Family 14
3.3.3 CMGC Family 15
3.3.4 CK1 Family 16
3.3.5 STE Family 17
3.3.6 TK Family 18
3.3.7 TKL Family 19
3.3.8 Atypical Protein Kinases 20
3.4 Protein Kinases as Therapeutic Targets 21
3.4.1 The Cell Surface Kinases 21
3.4.2 The Cytoplasmic Protein Kinases 21

4 Protein Kinases Pipeline Status for Major Indications 22
4.1 Oncology 24
4.1.1 Introduction 24
4.1.2 Pipeline Profile 24
4.1.3 Pipeline Analysis of Companies with Three or More Pipeline Molecules 25
4.1.4 NDA Applications Filed in Oncology 27
4.1.5 Phase III Pipeline Analysis Based on First-in-Class and Combination Drugs 27
4.2 Hematological Disorders 28
4.2.1 Introduction 28
4.2.2 Pipeline Analysis 28
4.3 Immunology 32
4.3.1 Introduction 32
4.3.2 Pipeline Analysis 32
4.4 Metabolic Disorders 36
4.4.1 Introduction 36
4.4.2 Pipeline Analysis 36
4.5 Central Nervous System 39
4.5.1 Introduction 39
4.5.2 Pipeline Analysis 40
4.6 Cardiovascular Diseases 44
4.6.1 Introduction 44
4.6.2 Pipeline Analysis 44
4.7 Ophthalmology 46
4.7.1 Introduction 46
4.7.2 Pipeline Analysis 46

5 Protein Kinases Current Pipeline Analysis 49
5.1 Protein Kinases Pipeline Overview 49
5.2 Protein Kinase Pipeline Profile of Top 10 Companies 50
5.3 Pfizer 52
5.3.1 Overview 52
5.3.2 Pipeline Analysis 52
5.3.3 Key Indications of Interest 53
5.3.4 First-in-Class and Combination Drugs 54
5.4 GlaxoSmithKline plc 62
5.4.1 Overview 62
5.4.2 Pipeline Analysis 62
5.4.3 Key Indications of Interest 63
5.4.4 First-in-Class and Combination Drugs 64
5.5 Eli Lilly and Company 69
5.5.1 Overview 69
5.5.2 Pipeline Analysis 69
5.5.3 Key Indications of Interest 70
5.5.4 First-in-Class and Combination Drugs 71
5.6 AstraZeneca PLC 77
5.6.1 Overview 77
5.6.2 Pipeline Analysis 78
5.6.3 Key Indications of Interest 79
5.6.4 First-in-Class and Combination Drugs 80
5.7 F. Hoffmann-La Roche Ltd. 85
5.7.1 Overview 85
5.7.2 Pipeline Analysis 85
5.7.3 Key Indications of Interest 86
5.7.4 First-in-Class and Combination Drugs 87
5.8 Novartis 90
5.8.1 Overview 90
5.8.2 Pipeline Analysis 90
5.8.3 Key Indications of Interest 91
5.8.4 First-in-Class and Combination Drugs 92
5.9 Exelixis, Inc. 95
5.9.1 Overview 95
5.9.2 Pipeline Analysis 95
5.9.3 Key Indications of Interest 96
5.9.4 First-in-Class and Combination Drugs 97
5.10 Boehringer Ingelheim GmbH 100
5.10.1 Overview 100
5.10.2 Pipeline Analysis 100
5.10.3 Key Indications of Interest 101
5.10.4 First-in-Class and Combination Drugs 102
5.11 Merck Inc. 105
5.11.1 Overview 105
5.11.2 Pipeline Analysis 105
5.11.3 Key Indications of Interest 106
5.11.4 First-in-Class and Combination Drugs 107
5.12 Takeda Pharmaceutical Company Limited 111
5.12.1 Overview 111
5.12.2 Pipeline Analysis 111
5.12.3 Key Indications of Interest 112
5.12.4 First-in-Class and Combination Drugs 113

6 Proetin Kinases Trends in Patenting 115

7 Protein Kinases Key Strategies for Innovation in Protein Kinases 116

7.1 Translational Science to Explore Multiple Disease Indications of Pipeline Drugs 116
7.2 The Strategy of Drug Combinations will Play a Significant Role in Development Programs 116
7.3 Focused Strategy for Drug Development 116
7.4 Functional Genomics 116
7.5 Distinctive R&D Strategies 116

8 Appendix 117
8.1 Market Definitions 117
8.2 Abbreviations 117
8.3 Research Methodology 117
8.3.1 Coverage 118
8.3.2 Secondary Research 118
8.3.3 Primary Research 118
8.3.4 Expert Panel Validation 118
8.4 Contact Us 119
8.5 Disclaimer 119
8.6 Sources 119

List of Table


Table 1: Innovations in Protein Kinase Therapies Protein Kinase Classification 12
Table 2: Innovations in Protein Kinase Therapies Indication-Wise Protein Kinase Pipeline Status, 2010 23
Table 3: Innovations in Protein Kinase Therapies Oncology Pipeline Profile, 2010 24
Table 4: Innovations in Protein Kinase Therapies Companies With More Than Three Oncology Phase III Pipeline Molecules, 2010 26
Table 5: Innovations in Protein Kinase Therapies NDA Applications Filed for Oncology Pipeline Molecules, 2010 27
Table 6: Innovations in Protein Kinase Therapies Hematological Disorders Pipeline Status, 2010 28
Table 7: Innovations in Protein Kinase Therapies List of Protein Kinase Pipeline Molecules in Hematological Disorders 29
Table 8: Innovations in Protein Kinase Therapies Immunology Pipeline Status, 2010 32
Table 9: Innovations in Protein Kinase Therapies List of Protein Kinase Pipeline Molecules in Immunology 33
Table 10: Innovations in Protein Kinase Therapies Metabolic Disorders Pipeline Status, 2010 36
Table 11: Innovations in Protein Kinase Therapies List of Protein Kinase Pipeline Molecules in Metabolic Disorders 37
Table 12: Innovations in Protein Kinase Therapies Central Nervous System Pipeline Status, 2010 40
Table 13: Innovations in Protein Kinase Therapies List of Protein Kinase Pipeline Molecules in Central Nervous System 41
Table 14: Innovations in Protein Kinase Therapies Cardiovascular Diseases Pipeline Status, 2010 44
Table 15: Innovations in Protein Kinase Therapies List of Protein Kinase Pipeline Molecules in Cardiovascular Diseases 45
Table 16: Innovations in Protein Kinase Therapies Ophthalmology Pipeline Status, 2010 46
Table 17: Innovations in Protein Kinase Therapies List of Protein Kinase Pipeline Molecules in Ophthalmology 47
Table 18: Innovations in Protein Kinase Therapies Overview of Protein Kinase Pipeline for all the Indications, 2010 49
Table 19: Innovations in Protein Kinase Therapies Protein Kinase Pipeline Status of Top 10 Companies, 2010 51
Table 20: Innovations in Protein Kinase Therapies Pfizer Protein Kinase Pipeline Status, 2010 52
Table 21: Innovations in Protein Kinase Therapies, Pfizer, No. of Protein Kinase Molecules Based on Indication, 2010 53
Table 22: Innovations in Protein Kinase Therapies List of Pfizer Protein Kinase Pipeline Studies 54
Table 23: Innovations in Protein Kinase Therapies GlaxoSmithKline Protein Kinases Pipeline Status, 2010 62
Table 24: Innovations in Protein Kinase Therapies GlaxoSmithKline, No. of Protein Kinase Molecules Based on Indication, 2010 63
Table 25: Innovations in Protein Kinase Therapies List of GlaxoSmithKline Protein Kinase Pipeline Studies 64
Table 26: Eli Lilly Protein Kinases Pipeline Status, 2010 69
Table 27: Innovations in Protein Kinase Therapies Eli Lilly, No. of Protein Kinase Molecules Based on Indication, 2010 70
Table 28: Innovations in Protein Kinase Therapies List of Eli Lilly Protein Kinase Pipeline Studies 71
Table 29: Innovations in Protein Kinase Therapies AstraZeneca Protein Kinases Pipeline Status, 2010 78
Table 30: Innovations in Protein Kinase Therapies AstraZeneca, No. of Protein Kinase Molecules Based on Indication, 2010 79
Table 31: Innovations in Protein Kinase Therapies List of AstraZeneca Protein Kinase Pipeline Studies 80
Table 32: Innovations in Protein Kinase Therapies Roche Protein Kinases Pipeline Status, 2010 85
Table 33: Innovations in Protein Kinase Therapies Roche, No. of Protein Kinase Molecules Based on Indication, 2010 86
Table 34: Innovations in Protein Kinase Therapies List of Roche Protein Kinase Pipeline Studies 87
Table 35: Innovations in Protein Kinase Therapies Novartis Protein Kinases Pipeline Status, 2010 90
Table 36: Innovations in Protein Kinase Therapies Novartis, No. of Protein Kinase Molecules Based on Indication, 2010 91
Table 37: Innovations in Protein Kinase Therapies List of Novartis Protein Kinase Pipeline Studies 92
Table 38: Innovations in Protein Kinase Therapies Exelixis Protein Kinases Pipeline Status, 2010 95
Table 39: Innovations in Protein Kinase Therapies Exelixis, No. of Protein Kinase Molecules Based on Indication, 2010 96
Table 40: Innovations in Protein Kinase Therapies List of Exelixis Protein Kinase Pipeline Studies 97
Table 41: Innovations in Protein Kinase Therapies Boehringer Ingelheim Protein Kinases Pipeline Status, 2010 100
Table 42: Innovations in Protein Kinase Therapies Boehringer Ingelheim, No. of Protein Kinase Molecules Based on Indication, 2010 101
Table 43: Innovations in Protein Kinase Therapies List of Boehringer Ingelheim Protein Kinase Pipeline Studies 102
Table 44: Innovations in Protein Kinase Therapies Merck Protein Kinases Pipeline Status, 2010 105
Table 45: Innovations in Protein Kinase Therapies Merck, No. of Protein Kinase Molecules Based on Indication, 2010 106
Table 46: Innovations in Protein Kinase Therapies List of Merck Protein Kinase Pipeline Studies 107
Table 47: Innovations in Protein Kinase Therapies Takeda Protein Kinases Pipeline Status, 2010 111
Table 48: Innovations in Protein Kinase Therapies Takeda, No. of Protein Kinase Molecules Based on Indication, 2010 112
Table 49: Innovations in Protein Kinase Therapies List of Takeda Protein Kinase Pipeline Studies 113

List of Chart


Figure 1: Innovations in Protein Kinase Therapies The Human Kinome Family 11
Figure 2: Innovations in Protein Kinase Therapies AGC Family Kinases 13
Figure 3: Innovations in Protein Kinase Therapies CAMK Family Kinases 14
Figure 4: Innovations in Protein Kinase Therapies CMGC Family Kinases 15
Figure 5: Innovations in Protein Kinase Therapies CK1 Family Kinases 16
Figure 6: Innovations in Protein Kinase Therapies STE Family Kinases 17
Figure 7: Innovations in Protein Kinase Therapies TK Family Kinases 18
Figure 8: Innovations in Protein Kinase Therapies TKL Family Kinases 19
Figure 9: Innovations in Protein Kinase Therapies Atypical Family Kinases 20
Figure 10: Innovations in Protein Kinase Therapies Protein Kinases in Development for Major Indications 22
Figure 11: Innovations in Protein Kinase Therapies Oncology Pipeline Profile, 2010 24
Figure 12: Innovations in Protein Kinase Therapies Oncology Phase III Pipeline Analysis of Companies With Three or More Pipeline Molecules, 2010 25
Figure 13: Innovations in Protein Kinase Therapies Oncology Phase III Pipeline Analysis Based on First-in-Class and Combination Drugs, 2010 27
Figure 14: Innovations in Protein Kinase Therapies Hematological Disorders Pipeline Profile, 2010 28
Figure 15: Innovations in Protein Kinase Therapies Immunology Pipeline Profile, 2010 32
Figure 16: Innovations in Protein Kinase Therapies Metabolic Disorders Pipeline Profile, 2010 36
Figure 17: Innovations in Protein Kinase Therapies Central Nervous System Pipeline Profile, 2010 40
Figure 18: Innovations in Protein Kinase Therapies Cardiovascular Diseases Pipeline Profile, 2010 44
Figure 19: Innovations in Protein Kinase Therapies Ophthalmology Pipeline Profile, 2010 46
Figure 20: Innovations in Protein Kinase Therapies Protein Kinases Pipeline Overview, 2010 49
Figure 21: Innovations in Protein Kinase Therapies Protein Kinase Pipeline Profile of Top 10 Companies, 2010 50
Figure 22: Innovations in Protein Kinase Therapies Pfizer Protein Kinases Phase-Wise Pipeline Profile, 2010 52
Figure 23: Innovations in Protein Kinase Therapies Pfizer Protein Kinase Pipeline Status for Various Indications, 2010 53
Figure 24: Innovations in Protein Kinase Therapies GlaxoSmithKline Protein Kinases Pipeline Profile, 2010 62
Figure 25: Innovations in Protein Kinase Therapies GlaxoSmithKline Protein Kinase Pipeline Status for Various Indications, 2010 63
Figure 26: Innovations in Protein Kinase Therapies Eli Lilly Protein Kinases Pipeline Profile, 2010 69
Figure 27: Innovations in Protein Kinase Therapies Eli Lilly Protein Kinase Pipeline Status for Various Indications, 2010 70
Figure 28: Innovations in Protein Kinase Therapies AstraZeneca Protein Kinases Pipeline Profile, 2010 78
Figure 29: Innovations in Protein Kinase Therapies AstraZeneca Protein Kinase Pipeline Status for Various Indications, 2010 79
Figure 30: Innovations in Protein Kinase Therapies Roche Protein Kinases Pipeline Profile, 2010 85
Figure 31: Innovations in Protein Kinase Therapies Roche Protein Kinase Pipeline Status for Various Indications, 2010 86
Figure 32: Innovations in Protein Kinase Therapies Novartis Protein Kinases Pipeline Profile, 2010 90
Figure 33: Innovations in Protein Kinase Therapies Novartis Protein Kinase Pipeline Status for Various Indications, 2010 91
Figure 34: Innovations in Protein Kinase Therapies Exelixis Protein Kinases Pipeline Profile, 2010 95
Figure 35: Innovations in Protein Kinase Therapies Exelixis Protein Kinase Pipeline Status for Various Indications, 2010 96
Figure 36: Innovations in Protein Kinase Therapies Boehringer Ingelheim Protein Kinases Pipeline Profile, 2010 100
Figure 37: Innovations in Protein Kinase Therapies Boehringer Ingelheim Protein Kinase Pipeline Status for Various Indications, 2010 101
Figure 38: Innovations in Protein Kinase Therapies Merck Protein Kinases Pipeline Profile, 2010 105
Figure 39: Innovations in Protein Kinase Therapies Merck Protein Kinase Pipeline Status for Various Indications, 2010 106
Figure 40: Innovations in Protein Kinase Therapies Takeda Protein Kinases Pipeline Profile, 2010 111
Figure 41: Innovations in Protein Kinase Therapies Takeda Protein Kinase Pipeline Status for Various Indications, 2010 112
Figure 42: Major Trends in Protein Kinases Patenting, 2010 115

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *